1188 GS-6620, A LIVER-TARGETED NUCLEOTIDE PRODRUG, EXHIBITS ANTIVIRAL ACTIVITY AND FAVORABLE SAFETY PROFILE OVER 5 DAYS IN TREATMENT NAIVE CHRONIC HCV GENOTYPE 1 SUBJECTS
E.J. Lawitz, M. Rodríguez‐Torres(Puerto Rico Community Foundation), Rachel Morrison, Lynn R. Webster(Adherent Technologies (United States)), Adrian S. Ray(Maine Farmland Trust), Daniel Gruener, Sandra Rossi(University of Parma), Lydie Hazan(AXIS Clinical Trials), E. Svaroskaia, R. Majuskas, Sarah Arterburn(Gilead Sciences (United States)), T. Marbury, M. DiMcco, Anil Jain(National Academy of Sciences India), D. Stefanidis, J. McHutchson, Jacqueline Hill, Polina German(Cytokinetics (United States))
Cited by 11
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
|Gastroenterology|2006|882